Study on Protein Receptor’s Role in IBD Supports Decision to Develop Blocking Therapy, OSE Says

Study on Protein Receptor’s Role in IBD Supports Decision to Develop Blocking Therapy, OSE Says
A study that OSE Immunotherapeutics conducted on the role that a protein receptor plays in bowel disease supports its development of a treatment that blocks the receptor, the company reports. It designed OSE-127 (Effi-7) to help inflammatory bowel disease patients who fail to respond to treatments that suppress their immune system. OSE-127 blocks the interleukin-7 receptor. OSE presented the

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *